Phio Pharmaceuticals Corp. announced on February 20, 2025, the appointment of Mr. David H. Deming to its Board of Directors, effective February 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following his appointment, the Board now comprises 6 directors, with 5 of whom are independent.
Mr. Deming brings over 30 years of extensive experience in investment banking and asset management to Phio Pharmaceuticals. He spent over 27 years with JP Morgan, where he notably led the Health Group in investment banking for 12 years. His background also includes developing the SmartNest 401(k) asset allocation product at Integrated Finance Limited.
Robert Bitterman, CEO and Chairman of the Board, stated that Mr. Deming's experience in the biopharma sector and corporate board service provides a valuable resource to Phio. This appointment is expected to strengthen the company's strategic direction as it advances its gene silencing technology for cancer treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.